Why Haemonetics Stock Was on Fire Thursday
2025-11-07 12:47:51 ET
Niche healthcare stock Haemonetics (NYSE: HAE) was a winner among the clutch of publicly traded companies reporting quarterly earnings on Thursday. On the back of an estimates-beating second quarter of fiscal 2026, investors piled into its shares to push them in excess of 32% higher. That looked particularly impressive next to the bellwether S&P 500 's (SNPINDEX: ^GSPC) 1.1% drop that trading session. On Friday, the rally continued, as the stock was up by over 3% that morning.
Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst expectation of under $312 million.
Image source: Getty Images.
NASDAQ: HAE
HAE Trading
0.13% G/L:
$59.65 Last:
182,586 Volume:
$60.29 Open:
